By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aclaris Therapeutics 

101 Lindenwood Drive
Suite 400
Malvern  Pennsylvania  19355  U.S.A.
Phone: 484-324-7933 Fax: 484-324-7949



Company News
Aclaris (ACRS) Release: Pharma Announces Appointment Of Andrew Powell To Board Of Directors 1/26/2017 7:37:22 AM
Aclaris (ACRS) Initiates Phase I Clinical Trial For ATI-50001, An Investigational JAK Inhibitor, For The Treatment Of Alopecia Totalis And Alopecia Universalis 12/7/2016 7:54:04 AM
Aclaris (ACRS) Announces Pricing Of Public Offering Of Common Stock 11/18/2016 7:27:30 AM
Aclaris (ACRS) Announces Proposed Public Offering Of Common Stock 11/17/2016 7:46:55 AM
Aclaris (ACRS) Announces Positive Top-Line Phase III Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition 11/16/2016 8:02:05 AM
Aclaris (ACRS) Reports Third Quarter 2016 Financial Results 11/3/2016 10:49:14 AM
Aclaris (ACRS) Submits Investigational New Drug Application For ATI-50001 To Treat Alopecia Universalis And Alopecia Totalis 10/31/2016 8:01:25 AM
Aclaris (ACRS) Honored As One Of The Best Places To Work In Pennsylvania 10/28/2016 7:56:31 AM
Aclaris (ACRS) To Announce Third Quarter 2016 Financial Results On November 3, 2016 10/25/2016 8:12:33 AM
Aclaris (ACRS) Release: New Observational Study Demonstrates Patient Impact Of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans 10/19/2016 8:09:37 AM